Market Snapshot
S&P Futures
3,914.75
Dow Futures
31,478
Nasdaq Futures
12,132.75
Axcella Health Inc. (AXLA) stock rallied over 0.53% intraday to trade at $1.88 a share on NASDAQ. The stock opened with a gain of 1.08% at $1.86 and touched an intraday high of $1.913, rising 0.53% against the last close of $1.87. The stock went to a low of $1.81 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-23 | $1.86 | $1.913 | $1.81 | $1.88 | 26,000 |
2022-06-22 | $1.86 | $2.017 | $1.85 | $1.87 | 49,000 |
2022-06-21 | $1.87 | $1.99 | $1.8 | $1.93 | 125,800 |
2022-06-17 | $2.3 | $2.45 | $1.8 | $1.8 | 333,500 |
2022-06-16 | $2.19 | $2.35 | $2.1 | $2.33 | 82,400 |
2022-06-15 | $2.2 | $2.34 | $2.05 | $2.25 | 66,200 |
2022-06-14 | $2.09 | $2.29 | $2.02 | $2.19 | 69,100 |
2022-06-13 | $1.91 | $2.26 | $1.91 | $2.12 | 108,400 |
2022-06-10 | $2.64 | $2.72 | $2 | $2 | 201,600 |
2022-06-09 | $2.79 | $2.79 | $2.639 | $2.74 | 87,200 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Axcella Health Inc. (NASDAQ: AXLA) stock price is $1.88 as of the last check on Thursday, June 23. During the trading session, AXLA stock reached the peak price of $1.913 while $1.81 was the lowest point it dropped to.
The NASDAQ listed AXLA is part of Biotechnology industry that operates in the broader Health Care sector. Axcella Health Inc. operates as a clinical stage biotechnology company in the United States.
Mr. Jason Fredette
VP of Investor Relations & Corp. Communications
Dr. Alison D. Schecter M.D.
Pres of R&D
Mr. William R. Hinshaw Jr.
Pres, CEO & Director
Dr. Alison D. Schecter M.D.
Pres of R&D, Strategy and Operations
AXLA stock traded closed the last session at $1.88, which is $0.01 or 0.53% lower than its previous close of $1.87. AXLA's current trading price is 39.26% lower than its 52-week high of $4.81 where as its distance from 52-week low of 1.35% is -60.91%.
Number of AXLA employees currently stands at -. AXLA operates from 840 Memorial Drive, 3rd Floor, Cambridge, MA 02139, United States.
Official Webiste of $AXLA is: https://www.axcellahealth.com
AXLA could be contacted at AXLA operates from 840 Memorial Drive, 3rd Floor, Cambridge, MA 02139, United States, or at phone #857 320 2200 and can also be accessed through its website.
AXLA stock volume for the day was 25,988 shares while in the previous session number of AXLA shares traded was 26,000 . The average number of AXLA shares traded daily for last 3 months was 71.54 Thousands.
The percentage change in AXLA stock occurred in the recent session was 0.53% while the dollar amount for the price change in AXLA stock was $0.01.
In the recent session, the day high for AXLA stock was $1.913 while the low for AXLA stock touched on the day was $1.81.
The market value of AXLA currently stands at 127.95 Million with its latest stock price at $1.88 and 41.43 Million of its shares outstanding.